IBM announced on Wednesday (19) a partnership so that its Watson supercomputer is used in a project of genetic medicine to help in personalized treatment of cancer patients.
The program of the Center for Genome New York (NYGC) will allow physicians to tailor the treatment to the genetic profile of each patient.The first phase of the project will focus on patients with glioblastoma, a brain tumor that kills 13,000 people a year in the U.S..
To enjoy the potencila processing supercomputer Watson will seek studies and clinical data in the medical journal to link them to genetic mutations of patients. “The doctors have very little time, and not have the tools necessary to offer treatments to their patients based on their DNA,” reported NYGC and IBM in a joint statement.
“This joint initiative want to accelerate the complex process by identifying patterns in gene sequence and medical data, to create opportunities that help doctors to carry the promise of genetic medicine to their patients.”
The president and scientific director of NYGC, Robert Darnell, said that since the sequencing of the human genome, for over 10 years, “the real challenge we face is how to make sense of the massive amount of data and transform that information into better treatments for patients. “
IBM had already associate in September 2011 to the insurance company WellPoint to implement the first commercial application of the calculation capabilities of Watson, developed to help doctors make diagnoses and treat their patients.
The supercomputer gained fame in February 2010 after winning two human champions at the game of questions and answers “Jeopardy!” Traditional program on American television.
Watson, named after IBM fundadador, Thomas Watson, uses a series of algorithms to determine extremely quickly which the response is more likely to be correct.